Billionaire philanthropist and Citadel CEO Ken Griffin has donated $15 million to Mount Sinai Medical Center to help expand ...

Neuralink, Elon Musk’s brain chip company, has partnered with researchers in Spain and California on a new clinical trial for what’s being called a “Smart Bionic Eye.” The trial quietly appeared on ...

India has the potential to turn that principle into practice by making the next generation of therapies not only practical but also accessible and affordable. If it succeeds, India won’t just lead the ...

The Revell family hoped a gene therapy could buy time for their sons, who have a rare and fatal disease. After two patients died, the drug’s manufacturer halted dosing under pressure from the FDA.

In an open letter, the heads of university medical schools in Scotland warn that the number of clinical academics is declining at an ...

Experts warn that Scotland's supply of clinical academics is declining at an "alarming rate," which could potentially ...

We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. BeOne Medicines Ltd.

Mount Sinai Medical Center today announced a transformational $15 million gift from Kenneth C. Griffin, founder and CEO of Citadel and founder of Griffin Catalyst. The gift supports the new Braman Com ...

Q4 Fiscal 2024 Highlights1Revenue of $1.2 million, a 16.4% increase over Q3 2024Gross profit of $0.3 million, compared to a loss of $0.05 million in Q3 2024Cash position of $2.0 million as of August 3 ...

There is an urgent need for more inclusive and community-focused cancer clinical trials, according to Kimberly (Cary) ...

Inidascamine was well-tolerated, with a favorable safety profile consistent with previous studies. Importantly, no evidence of sedation, weight gain, or extrapyramidal symptoms was observed, which are ...

A poster at the Society for Pediatric Dermatology Annual Meeting presented an integrated safety analysis showing rare or no serious adverse events linked to topical Janus kinase inhibitor use in ...